MARC details
| 000 -LEADER |
|---|
| fixed length control field |
04196nam a22005657a 4500 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
180220s20182018 xxu||||| |||| 00| 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER |
|---|
| International Standard Serial Number |
1748-717X |
| 024 ## - OTHER STANDARD IDENTIFIER |
|---|
| Standard number or code |
10.1186/s13014-018-0969-2 [doi] |
| 024 ## - OTHER STANDARD IDENTIFIER |
|---|
| Standard number or code |
10.1186/s13014-018-0969-2 [pii] |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
Ovid MEDLINE(R) |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
|---|
| PMID |
29439707 |
| 245 ## - TITLE STATEMENT |
|---|
| Title |
Stereotactic Body Radiotherapy (SBRT) for liver metastasis - clinical outcomes from the international multi-institutional RSSearch Patient Registry. |
| 251 ## - Source |
|---|
| Source |
Radiation Oncology. 13(1):26, 2018 Feb 13 |
| 252 ## - Abbreviated Source |
|---|
| Abbreviated source |
Radiat. oncol.. 13(1):26, 2018 Feb 13 |
| 253 ## - Journal Name |
|---|
| Journal name |
Radiation oncology (London, England) |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Year |
2018 |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Manufacturer |
FY2018 |
| 265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE] |
|---|
| Publication status |
epublish |
| 266 ## - Date added to catalog |
|---|
| Date added to catalog |
2018-02-20 |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
BACKGROUND: Stereotactic body radiotherapy (SBRT) is an emerging treatment option for liver metastases in patients unsuitable for surgery. We investigated factors associated with clinical outcomes for liver metastases treated with SBRT from a multi-center, international patient registry. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
CONCLUSIONS: In a large, multi-institutional series of patients with liver metastasis treated with SBRT, reasonable LC and OS was observed. OS and LC depended on dose and tumor volume, while OS varied by primary tumor. Future prospective trials on the role of SBRT for liver metastasis from different primaries in the setting of multidisciplinary management including systemic therapy, is warranted. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
METHODS: Patients with liver metastases treated with SBRT were identified in the RSSearch Patient Registry. Patient, tumor and treatment characteristics associated with treatment outcomes were assessed. Dose fractionations were normalized to BED<sub>10</sub>. Overall survival (OS) and local control (LC) were evaluated using Kaplan Meier analysis and log-rank test. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
RESULTS: The study included 427 patients with 568 liver metastases from 25 academic and community-based centers. Median age was 67 years (31-91 years). Colorectal adenocarcinoma (CRC) was the most common primary cancer. 73% of patients received prior chemotherapy. Median tumor volume was 40 cm<sup>3</sup> (1.6-877 cm<sup>3</sup>), median SBRT dose was 45 Gy (12-60 Gy) delivered in a median of 3 fractions [1-5]. At a median follow-up of 14 months (1-91 months) the median overall survival (OS) was 22 months. Median OS was greater for patients with CRC (27 mo), breast (21 mo) and gynecological (25 mo) metastases compared to lung (10 mo), other gastro-intestinal (GI) (18 mo) and pancreatic (6 mo) primaries (p<0.0001). Smaller tumor volumes (<40 cm<sup>3</sup>) correlated with improved OS (25 months vs 15 months p=0.0014). BED<sub>10</sub>>=100 Gy was also associated with improved OS (27 months vs 15 months p<0.0001). Local control (LC) was evaluable in 430 liver metastases from 324 patients. Two-year LC rates was better for BED<sub>10</sub>>=100 Gy (77.2% vs 59.6%) and the median LC was better for tumors <40 cm<sup>3</sup> (52 vs 39 months). There was no difference in LC based on histology of the primary tumor. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
TRIAL REGISTRATION: Clinicaltrials.gov: NCT01885299 . |
| 546 ## - LANGUAGE NOTE |
|---|
| Language note |
English |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Liver Neoplasms/sc [Secondary] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Liver Neoplasms/su [Surgery] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Radiosurgery |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Registries/sn [Statistics & Numerical Data] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Adult |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Aged |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Aged, 80 and over |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Female |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Follow-Up Studies |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Humans |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
International Agencies |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Male |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Middle Aged |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Prognosis |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Radiotherapy Dosage |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Retrospective Studies |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Survival Rate |
| 651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME |
|---|
| Institution |
Washington Cancer Institute |
| 657 ## - INDEX TERM--FUNCTION |
|---|
| Medline publication type |
Journal Article |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Local Authors |
Perry, David J |
| 790 ## - Authors |
|---|
| All authors |
Blanck O, D'Ambrosio D, Davis J, Kolker J, Lanciano R, Mahadevan A, Peddada A, Perry D, Sharma S, Sundararaman S |
| 856 ## - ELECTRONIC LOCATION AND ACCESS |
|---|
| DOI |
<a href="https://dx.doi.org/10.1186/s13014-018-0969-2">https://dx.doi.org/10.1186/s13014-018-0969-2</a> |
| Public note |
https://dx.doi.org/10.1186/s13014-018-0969-2 |
| 858 ## - ORCID |
|---|
| ORCID text |
Mahadevan, Anand |
| Orcid |
<a href="http://orcid.org/0000-0003-3555-4217">http://orcid.org/0000-0003-3555-4217</a> |
| Name |
http://orcid.org/0000-0003-3555-4217 |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Koha item type |
Journal Article |
| Item type description |
Article |
